Stereotactic body radiotherapy for stage I lung cancer and small lung metastasis: evaluation of an immobilization system for suppression of respiratory tumor movement and preliminary results

Baba, Fumiya; Shibamoto, Yuta; Tomita, Natsuo; Ikeya-Hashizume, Chisa; Oda, Kyota; Ayakawa, Shiho; Ogino, Hiroyuki; Sugie, Chikao
January 2009
Radiation Oncology;2009, Vol. 4, p1
Academic Journal
Background: In stereotactic body radiotherapy (SBRT) for lung tumors, reducing tumor movement is necessary. In this study, we evaluated changes in tumor movement and percutaneous oxygen saturation (SpO2) levels, and preliminary clinical results of SBRT using the BodyFIX immobilization system. Methods: Between 2004 and 2006, 53 consecutive patients were treated for 55 lesions; 42 were stage I non-small cell lung cancer (NSCLC), 10 were metastatic lung cancers, and 3 were local recurrences of NSCLC. Tumor movement was measured with fluoroscopy under breath holding, free breathing on a couch, and free breathing in the BodyFIX system. SpO2 levels were measured with a finger pulseoximeter under each condition. The delivered dose was 44, 48 or 52 Gy, depending on tumor diameter, in 4 fractions over 10 or 11 days. Results: By using the BodyFIX system, respiratory tumor movements were significantly reduced compared with the free-breathing condition in both craniocaudal and lateral directions, although the amplitude of reduction in the craniocaudal direction was 3 mm or more in only 27% of the patients. The average SpO2 did not decrease by using the system. At 3 years, the local control rate was 80% for all lesions. Overall survival was 76%, cause-specific survival was 92%, and local progression-free survival was 76% at 3 years in primary NSCLC patients. Grade 2 radiation pneumonitis developed in 7 patients. Conclusion: Respiratory tumor movement was modestly suppressed by the BodyFIX system, while the SpO2 level did not decrease. It was considered a simple and effective method for SBRT of lung tumors. Preliminary results were encouraging.


Related Articles

  • Lung Cancer, Other Minimally Invasive Radiation Therapy Treatments Focus of International Radiation Oncology Conference.  // Ascribe Newswire: Medicine;6/1/2004, p1 

    The article presents information about the third annual Conference on "Stereotactic Body Radiation Therapy," will be May 21-23. The latest options with stereotactic radiation treatments will be presented, including information on a promising lung cancer trial that has received National...

  • Developments in early-stage NSCLC: advances in radiotherapy. Verstegen, N. E.; Lagerwaard, F. J.; Senan, S. // Annals of Oncology;Sep2012 Supplement 10, Vol. 23 Issue suppl_10, px46 

    An increase in the number of predominantly elderly patients with early-stage non-small-cell lung cancer is anticipated in many Western populations. Patients often have major co-morbidities and are at increased risk for surgical morbidity and mortality. In the past decade, the use of stereotactic...

  • Stereotactic body radiation controlled early-stage lung cancer tumors. Harris, Jason // Hem/Onc Today;4/25/2010, Vol. 11 Issue 8, p22 

    The article presents a study, published in the "Journal of the American Medical Association," which demonstrated how a two-week course of stereotactic body radiation therapy resulted in high rates of tumor control and possible improvement of survival for patients with inoperable early-stage...

  • Stereotactic radiotherapy, wedge resection options for borderline operable NSCLC.  // Hem/Onc Today;2/25/2010, Vol. 11 Issue 4, p43 

    The article discusses the use of stereotactic radiotherapy and wedge resection as options for borderline operable non-small cell lung cancer (NSCLC).

  • Adrenal Metastazlarda CyberKnife ile Stereotaktik Vücut Radyoterapisi. EKİCİ, Kemal; ÖZŞEKER, Naciye; MAYADAĞLI, Alpaslan; ÖZDEMİR DAĞ, Sedef; KURBAN, Fatma; ÖZYURT, Hazan; ALGÜL, Emriye; KILIÇOĞLU, Gamze // Journal of Kartal Training & Research Hospital / Kartal Egitim v;2013, Vol. 24 Issue 3, p164 

    Background: The aim of this study was to evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) for adrenal metastases. Methods: Between August 2011 and December 2012, five patients with adrenal metastases that originated from non small lung cancer were analyzed. Three...

  • STEREOTACTIC CONFORMAL RADIOTHERAPY IN PATIENTS WITH LUNG CANCER AND CARDIOVASCULAR PATHOLOGY. Anikeeva, O. Yu.; Polovnikov, E. S.; Bednyi, I. V.; Filatov, P. V. // Oncosurgery / Onkohirurgia;2012, Vol. 4 Issue 3, p23 

    The techniques of stereotactic radiotherapy in patients with non-small cell lung cancer with concurrent cardiovascular pathology with active breathing control system is represented in the article. Material and methods: stereotactic conformal radiotherapy was performed in 26 patients with...

  • Fractionated stereotactic radiotherapy for small-cell lung cancer patients with brain metastases. Xiang-Pan Li; Jian.Ping Xiao; Xiu-Jun Chen; Xue-Song Jiang; Ye Zhang; Ying-Jie Xu // Journal of Cancer Research & Therapeutics;Jul-Sep2014, Vol. 10 Issue 3, p597 

    Objective: Patients with small-cell lung cancer (SCLC) are at high risk of developing brain metastases (BM). Fractionated stereotactic radiotherapy (FSRT) alone or combined with whole brain radiation therapy can be used to treat intracranial metastases. This study was aimed to explore FSRT for...

  • Stereotactic Lung Cancer Study Produces Positive Initial Results.  // Ascribe Newswire: Medicine;11/10/2003, p13 

    The initial phase of a clinical trial for treatment of early stage lung cancer has produced positive results, according to an article appearing November 11, 2003 in the journal "Chest." Researchers at Indiana University School of Medicine reported that the results of the extracranial...

  • Role of EGFR Inhibitors in the Treatment of Central Nervous System Metastases from Non-Small Cell Lung Cancer. Ceresoli, G. L. // Current Cancer Drug Targets;Mar2012, Vol. 12 Issue 3, p237 

    Brain metastases (BM) are a common occurrence in patients with non-small cell lung cancer (NSCLC). Standard therapy options include whole brain radiotherapy and, in selected patients, surgery or stereotactic radiosurgery. The role of systemic treatment is controversial. There is a strong...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics